media – Page 647 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

US nod for CSL Behring’s HAE prevention therapy

US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary (HAE) attacks in adolescent and adults.
- Source: pharmatimes
- 433
- June 23, 2017
HAE inhibitor New Approvals
EU regulators review Novartis’ migraine drug

An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
- Source: pharmatimes
- 1,003
- June 22, 2017
antibody Clinical Trials erenumab EU New Approvals WHO
Ddu’s Golden Age in Cross-border Medical Trade

Under the background of the Internet plus era, Ddu is set up by a a talented team, consisting of experienced insiders and Internet elites. Ddu (Drugdu.com) is a global leading pharmaceuticals and medical devices B2B online platform. Different from comprehensive B2B platforms, Ddu is a vertical one focusing on the medical trade industry. It is a bold attempt for traditional industry to accelerate the transformation and upgrading.
- Source: Ddu
- 705
- June 22, 2017
cross-border medical device pharmaceutical
Drugdu.com (“Ddu”) will attend INTERPHEX JAPAN

INTERPHEX JAPAN will be held in Big Sight, Tokyo from June 28th - 30th. As the leading global pharmaceuticals and medical devices B2B online platform, Ddu will attend the fair with products from high priority members.
- Source: Ddu
- 559
- June 21, 2017
Exhibitions & Activities INTERPHEX JAPAN
A choice for Chang’an Pharmaceutical to win global orders

It is delighted that Chang'an Pharmaceutical became the 100th VIP member of Ddu. It is Ddu’s honor to invite Chang'an Pharmaceutical for the interview. Drugdu will continue to focus on the optimization of the online and offline services, committing to create more friendly, more humane medical trade ecosystem in the future.No matter it is the 1st member or the 1,000th one, Ddu will try the best. We are always with you.
- Source: drugdu
- 926
- June 20, 2017
Ddu News pharmaceutical
Global generic drug approvals up in 2016

The USFDA said that it has achieved a year early the target set for 2017, to take action on 90% of the applications pending prior to the start of the Generic Drug User Fee Amendment Act (GDUFA) of 2012.
- Source: Ddu
- 568
- June 17, 2017
FDA generic drug Market Reports
Owlstone’s search into breath biomarkers of cancer

Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
- Source: pharmatimes
- 523
- June 15, 2017
cancer Clinical Trials diagnostic therapy
Meet Drugdu.com (Ddu) at CPhI China 2017 for Global Business Partners

CPhI China 2017 will be held from 20th June to 22nd June 2017 at the Shanghai New International Expo Center (SNIEC) in Shanghai, China. Ddu, the leading global pharmaceuticals and medical devices B2B platform , will attend the exhibition with products from high-priority members and launch synchronization services of buy offers and agency service.
- Source: Ddu
- 990
- June 15, 2017
App CPhI Exhibitions & Activities
Merck pauses Keytruda studies to assess patient deaths

Merck has paused new enrolment in two studies assessing its immunotherapy Keytruda treatment in combination with other therapies in multiple myeloma to address safety concerns.
- Source: pharmatimes
- 479
- June 13, 2017
asthma Clinical Trials keytruda
Pioneering prostate biopsy device wins NIHR award

A new method for extracting prostate biopsies has been awarded a £789,000 Invention for Innovation (i4i) Product Development Award by the National Institute for Health Research (NIHR).
- Source: pharmatimes
- 515
- June 13, 2017
biopsy device Market Views NIHR

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.